CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRVO CervoMed

Trading 03-10 10:51:52 EDT

4.68

+0.14

+2.97%

High5.12	Low4.54	Vol74.96K
Open4.64	D1 Closing4.54	Amplitude12.78%
Mkt Cap43.26M	Tradable Cap23.07M	Total Shares9.25M
T/O364.09K	T/O Rate1.52%	Tradable Shares4.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":4.675,"timestamp":1773154289243,"preClose":4.54,"halted":0,"volume":74958,"delay":0,"changeRate":0.029735682819383213,"floatShares":4934300,"shares":9252719,"eps":-2.873156,"marketStatus":"Trading","change":0.135,"latestTime":"03-10 10:51:52 EDT","open":4.64,"high":5.12,"low":4.5399,"amount":364088.15639039996,"amplitude":0.127775,"askPrice":4.77,"askSize":240,"bidPrice":4.58,"bidSize":121,"shortable":3,"etf":0,"ttmEps":-2.873156,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773172800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":4.54,"preHourTrading":{"tag":"盘前","latestPrice":4.58,"preClose":4.54,"latestTime":"08:00 EDT","volume":8,"amount":36.64,"timestamp":1773144002303,"change":0.04,"changeRate":0.008811,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.54,"latestTime":"19:07 EDT","volume":8719,"amount":42603.7616,"timestamp":1773097671082,"change":0.21,"changeRate":0.046256,"amplitude":0.156388},"volumeRatio":2.641122},"requestUrl":"/m/hq/s/CRVO/tweets","defaultTab":"tweets","newsList":[{"id":"2617544221","title":"CervoMed to Participate in Leerink Global Healthcare Conference and 38th Annual ROTH Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2617544221","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617544221?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713837,"startTime":"0","endTime":"0","summary":"CervoMed to Participate in Leerink Global Healthcare Conference and 38th Annual ROTH Conference               CervoMed Inc. said management will participate in the Leerink Global Healthcare Conference","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL8gfHrZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","LU2095319765.USD","BK4139","LU2210150020.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","SG9999014005.SGD","BK4588","LU2210149790.SGD","CRVO","BK4585","LU0314104364.USD","IE00BKPKM429.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2617542907","title":"CervoMed to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2617542907","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617542907?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713800,"startTime":"0","endTime":"0","summary":"BOSTON, March  05, 2026  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/05/3250044/0/en/CervoMed-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2617656564","title":"CervoMed Advances Neflamapimod With Phase 1 Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2617656564","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617656564?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:44","pubTimestamp":1772660644,"startTime":"0","endTime":"0","summary":"The latest update is out from CervoMed ( ($CRVO) ). On March 4, 2026, CervoMed reported completion of a Phase 1 healthy volunteer study assessing t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-advances-neflamapimod-with-phase-1-completion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-advances-neflamapimod-with-phase-1-completion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2617565500","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2617565500","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617565500?lang=en_us&edition=fundamental","pubTime":"2026-03-05 03:55","pubTimestamp":1772654100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2026 14:55 ET (19:55 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2616582315","title":"CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2616582315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616582315?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:05","pubTimestamp":1772629504,"startTime":"0","endTime":"0","summary":"CervoMed Inc. highlighted its clinical-stage pipeline focused on age-related brain disorders, centered on its lead candidate neflamapimod, an oral small-molecule inhibitor of p38α intended to address neuroinflammation and synaptic dysfunction. The company outlined planned development steps for neflamapimod in dementia with Lewy bodies, including preparation for a Phase 3 study expected to initiate in the second half of 2026, and noted ongoing Phase 2a trials in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts anticipated in mid-2026 and the second half of 2026, respectively. The presentation also described prior Phase 2a and Phase 2b findings in dementia with Lewy bodies and discussed drug exposure differences between manufacturing batches used in the Phase 2b program. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. W","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL3yjjqz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2616530846","title":"BRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2616530846","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616530846?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:33","pubTimestamp":1772627603,"startTime":"0","endTime":"0","summary":"BRIEF-Cervomed Announces Selection Of Formulation And Dosing Regimen For Planned Phase 3 Trial In Patients With Dementia With Lewy BodiesMarch 4 (Reuters) - CervoMed Inc CRVO.O:CERVOMED ANNOUNCES SELE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA69F5X9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2616896530","title":"CervoMed selects 50mg TID neflamapimod dosing for planned Phase 3 DLB trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616896530","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616896530?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:31","pubTimestamp":1772627470,"startTime":"0","endTime":"0","summary":"CervoMed Inc. announced completion of a Phase 1 healthy volunteer study evaluating the pharmacokinetics of a drug product containing a new, stable crystal form of neflamapimod and selected a 50 mg three-times-daily dosing regimen for its planned Phase 3 trial in patients with dementia with Lewy bodies. The company said the higher dose is intended to achieve plasma drug concentrations associated with therapeutic activity observed previously with a clinically active drug product batch used in the extension phase of the Phase 2b RewinD-LB trial. CervoMed stated that additional results and comparative pharmacokinetic data are being made available in its corporate presentation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL8fQ4yY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CRVO","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4112","BK4585","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2616537003","title":"CervoMed Inc - to Initiate Global Phase 3 Trial in Dlb in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616537003","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616537003?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:30","pubTimestamp":1772627400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA69F5X9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2612245164","title":"CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2612245164","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612245164?lang=en_us&edition=fundamental","pubTime":"2026-02-19 05:35","pubTimestamp":1771450523,"startTime":"0","endTime":"0","summary":"Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on CervoMed. The associated price target remains the same with $20.00. Soumit R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomed-capital-efficient-expansion-of-neflamapimod-into-als-platform-trial-supports-buy-rating-and-20-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomed-capital-efficient-expansion-of-neflamapimod-into-als-platform-trial-supports-buy-rating-and-20-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2612444486","title":"CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2612444486","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612444486?lang=en_us&edition=fundamental","pubTime":"2026-02-18 23:16","pubTimestamp":1771427819,"startTime":"0","endTime":"0","summary":"CervoMed Inc. highlighted progress for its lead candidate neflamapimod, an oral small-molecule p38α inhibitor being developed for age-related brain disorders. The company outlined plans to initiate a Phase 3 trial in dementia with Lewy bodies in the second half of 2026, and said Phase 2a enrollment is ongoing in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts expected in mid-2026  and the second half of 2026 . The presentation also summarized prior DLB study findings, including Phase 2a results showing improvements on CDR-SB and gait measures, and Phase 2b extension-phase analyses in which participants receiving a drug product batch that achieved target plasma concentrations showed improved CDR-SB and ADCS-CGIC outcomes versus an earlier batch. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL8krSFZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2612443048","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2612443048","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612443048?lang=en_us&edition=fundamental","pubTime":"2026-02-18 20:47","pubTimestamp":1771418820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 07:47 ET (12:47 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2612174624","title":"CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2612174624","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612174624?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:16","pubTimestamp":1771413379,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) announced that neflamapimod, an oral small molecule drug candidate targeting critical disease processes underlying degenerative dis...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomeds-neflamapimod-elected-for-inclusion-in-uk-experts-als-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomeds-neflamapimod-elected-for-inclusion-in-uk-experts-als-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2612417996","title":"BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2612417996","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612417996?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:10","pubTimestamp":1771413035,"startTime":"0","endTime":"0","summary":"BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform Feb 18 (Reuters) - CervoMed Inc CRVO.O:CERVOMED’S NEFLAMAPIMOD ELECTED FOR INCLUSION IN UK EXPERTS-ALS PLATFORM DESIGNED ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nFWN3ZD1D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2612417553","title":"CervoMed: Maintain Focus on Dlb, Take Steps to Initiate Planned Phase 3 Trial Later This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2612417553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612417553?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:01","pubTimestamp":1771412508,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nFWN3ZD1D1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2612417362","title":"CervoMed’s Neflamapimod Elected for Inclusion in UK Experts-ALS Platform Designed to Prioritize Promising Treatments for Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2612417362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612417362?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:01","pubTimestamp":1771412508,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nFWN3ZD1D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2612417326","title":"CervoMed Inc - First ALS Patient Expected to Be Dosed by End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612417326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612417326?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:01","pubTimestamp":1771412508,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nFWN3ZD1D1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2612341731","title":"CervoMed Joins UK EXPERTS-ALS Trial Platform to Test Neflamapimod in ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2612341731","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612341731?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:00","pubTimestamp":1771412416,"startTime":"0","endTime":"0","summary":"CervoMed Inc. will collaborate with the UK EXPERTS-ALS clinical trial platform, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust and funded by the UK NIHR and leading motor neuron disease charities, to evaluate its drug candidate neflamapimod in amyotrophic lateral sclerosis. The randomized, multi-center platform trial will initially enroll about 35 ALS participants to assess neflamapimod’s impact on neurofilament light chain levels, with potential expansion to up to 80 patients. The first ALS patient is expected to be dosed by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire  on February 18, 2026, and is solely ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL2p65CV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","SG9999014039.USD","LU2210149790.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BK4588","BK4139","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BKPKM429.USD","BK4585","LU0314104364.USD","SG9999014013.SGD","IE00B64PRP62.GBP","CRVO","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2612414075","title":"CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely","url":"https://stock-news.laohu8.com/highlight/detail?id=2612414075","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612414075?lang=en_us&edition=fundamental","pubTime":"2026-02-18 18:04","pubTimestamp":1771409050,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvo/cervomed/news/cervomed-nasdaqcrvo-will-have-to-spend-its-cash-wisely","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvo/cervomed/news/cervomed-nasdaqcrvo-will-have-to-spend-its-cash-wisely","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TSYW.SI","QQQJ","SQQQ","QID","BK4139","JEPQ","NVIW.SI","QYLD","GPIQ","TQQQ","NQmain","CRVO","QQQY","MNQmain","PSQ","USAW.SI","QLD","QQQE","USJW.SI",".IXIC","QYLG"],"gpt_icon":1},{"id":"2603984238","title":"Alpha Buying: Managing Biotech Risk With Insider Clues","url":"https://stock-news.laohu8.com/highlight/detail?id=2603984238","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603984238?lang=en_us&edition=fundamental","pubTime":"2026-01-16 00:32","pubTimestamp":1768494720,"startTime":"0","endTime":"0","summary":"Biotech stocks have a way of making smart people do dumb things. It starts innocently enough.You read about a \"breakthrough\" that sounds like it came straight out of science fiction. A tiny company with a tiny market cap is working on a therapy that could change the standard of care.You picture the chart before you even open it. A little line. Then a rocket ship.You buy a starter position because you do not want to miss it, and you tell yourself you will add later if the story keeps getting better.And then biotech does what biotech always does. It reminds you that in this corner of the market, the business is not the product. The business is the trial.Then there is the information environment, which is a polite way of saying biotech is a narrative factory. The science is complex, the milestones are technical, and the incentives are obvious. Management wants to keep the story alive. Analysts want access. Retail investors want hope. Soci","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/15/Stock-Market-Analysis-With-Candlestick-C.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/15/Stock-Market-Analysis-With-Candlestick-C.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/26/01/49941880/alpha-buying-managing-biotech-risk-with-insider-clues","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/26/01/49941880/alpha-buying-managing-biotech-risk-with-insider-clues","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SMMT","ANNX","CRVO","LU2488822045.USD","BK4139"],"gpt_icon":0},{"id":"2602431396","title":"CervoMed Releases Updated Investor Presentation and Business Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=2602431396","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602431396?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:31","pubTimestamp":1767907917,"startTime":"0","endTime":"0","summary":"The latest update is out from CervoMed ( ($CRVO) ). On January 8, 2026, CervoMed Inc. disclosed that it has made an investor presentation available...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-releases-updated-investor-presentation-and-business-overview?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-releases-updated-investor-presentation-and-business-overview?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cervomed.com","stockEarnings":[{"period":"1week","weight":0.1671},{"period":"1month","weight":-0.145},{"period":"3month","weight":-0.4739},{"period":"6month","weight":-0.5231},{"period":"1year","weight":1.0543},{"period":"ytd","weight":-0.4253}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.04},{"period":"1year","weight":0.1777},{"period":"ytd","weight":-0.0054}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.023389},{"month":2,"riseRate":0.5,"avgChangeRate":0.085839},{"month":3,"riseRate":0.6,"avgChangeRate":0.341085},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.064048},{"month":5,"riseRate":0.444444,"avgChangeRate":0.146641},{"month":6,"riseRate":0.111111,"avgChangeRate":-0.121539},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.07795},{"month":8,"riseRate":0.666667,"avgChangeRate":0.076308},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.117703},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.039339},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.045938},{"month":12,"riseRate":0.3,"avgChangeRate":-0.206034}],"exchange":"NASDAQ","name":"CervoMed","nameEN":"CervoMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CervoMed,CRVO,CervoMed股票,CervoMed股票老虎,CervoMed股票老虎国际,CervoMed行情,CervoMed股票行情,CervoMed股价,CervoMed股市,CervoMed股票价格,CervoMed股票交易,CervoMed股票购买,CervoMed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction